Cannes Lions 2026 unveils the Pharma Lions shortlist, featuring 23 finalists that show how pharmaceutical creativity is connecting science, innovation, patients and healthcare professionals

June, 2026.- Cannes Lions 2026 has released the shortlist for the Pharma Lions category, one of the Festival’s most specialised competitions and a global benchmark for creativity in pharmaceutical communications, medical innovation and trust-building within highly regulated sectors.

The Pharma Lions celebrate creative communications for pharmaceutical clients, products and services, recognising work that brings science to life, explains medical conditions, promotes treatments, supports specialised education and connects with patients, caregivers, healthcare professionals and specific communities.

The 2026 Jury President for Pharma Lions is Tracey Brader, Chief Strategy and Innovation Officer at Omnicom Health, United Kingdom. Her leadership brings deep healthcare strategy, innovation and creative expertise to one of the industry’s most complex and tightly regulated categories.

The Pharma Lions 2026 shortlist includes 23 shortlisted entries, spanning Branded Product or Service Promotion, Unbranded Product or Service Promotion, Product or Service Promotion: Healthcare Professional, Disease Awareness & Understanding, Healthcare Professional Engagement and Patient Engagement.

The selection confirms that pharmaceutical creativity is entering a new phase, where brands, companies and agencies are not only communicating clinical benefits, but also creating ideas that educate, move people, simplify complex information and drive action among highly specific audiences.

In Branded Product or Service Promotion, shortlisted work includes “Viagra Blue Brands” by Viatris and Viagra; “Suzanne” by Eylea HD; and “Animal Attraction” by Gilead Sciences Canada for Descovy. These entries show how direct-to-consumer pharmaceutical communication can combine brand identity, storytelling, humour, film craft and cultural relevance within regulatory boundaries.

“Viagra Blue Brands”, created by Ogilvy Shanghai for Viatris, appears across two media in the shortlist: Integrated and Direct. Its presence highlights the ability of an iconic brand to update its language, broaden its conversation and continue building recognition in a highly sensitive category.

Unbranded Product or Service Promotion is the largest section of the shortlist, featuring entries such as “Get Body Checked Against Cancer” by AstraZeneca; “Relax Your Tight End” by Novartis; “Anything But Normal” by Bayer Women’s Health; “The HS Truths Anthem” by Incyte Corporation; “Your Attention Please” by Novartis; “1 for3” by GSK; and “Chamuyo (Dinosaur)” by MSD.

The strength of unbranded work points to a key trend in Pharma Lions 2026: disease education and medical-condition awareness are becoming major creative territories. These ideas open conversations without relying solely on direct product promotion, prioritising understanding, prevention, diagnosis, adherence and visibility.

Novartis stands out in the shortlist with “Relax Your Tight End” and “Your Attention Please”, two works appearing across different media and showing how pharmaceutical brands are exploring entertainment, sport, humour, activation, public relations and film content to elevate attention around health topics.

In Product or Service Promotion: Healthcare Professional, the shortlist includes “Gen See” by Izervay and “Voodoo Dolls” by Abbott Established Pharmaceuticals. This section underlines the importance of communicating with precision, credibility and creativity to healthcare professionals, researchers, key opinion leaders and scientific influencers.

In Disease Awareness & Understanding, shortlisted work includes “Sawaal Uthao” by Tata 1mg; “Skivolo’s World” by United Therapeutics Oncology; “Nyestalgia” by Biogen; “The Sound of COPD” by Chiesi Pharmaceuticals; and “The Safe Pack” by TuPharma 365. These campaigns show how creativity can help explain disease, reduce stigma, build community and improve understanding of conditions that require professional diagnosis or care.

The inclusion of “Skivolo’s World”, an animated series by United Therapeutics Oncology, demonstrates how entertainment can become a vehicle for education for families navigating complex medical journeys. The work shows that pharmaceutical communication can be empathetic, accessible and narrative while maintaining seriousness and rigour.

In Healthcare Professional Engagement, “See a Seizure” by Jazz Pharmaceuticals has been shortlisted. The work highlights the role of data, technology and specialised communication in supporting ongoing medical education and improving the recognition or understanding of neurological conditions.

In Patient Engagement, “Ready! Steady! Lenny!” by Genentech for Hemlibra has been selected, focusing on product innovation and patient support. Its inclusion highlights creativity’s role in treatment experience, adherence, daily care and better outcomes for people living with specific health conditions.

The shortlist brings together work from markets including Mainland China, the United States, Canada, the United Kingdom, Spain, Taiwan, Switzerland, India and the Netherlands. This geographic spread confirms that pharmaceutical creativity is growing as a global language, while remaining deeply shaped by local regulation, culture and healthcare realities.

The United States represents a significant share of the shortlisted work, with agencies and companies including Area 23, Grey Health, Fallon, FCB Health New York, Merkley + Partners, Neon, 21Grams and Genentech in South San Francisco. Its presence reflects the strength of the US market in direct pharmaceutical communication, health innovation and specialist healthcare marketing.

Work from Asia, Europe and North America also stands out, with entries from Ogilvy Shanghai, Ogilvy Taipei, VML London, VML Madrid, Weber Shandwick Geneva, Humour Me New Delhi, The Family Amsterdam and Klick Health Toronto, among other creative and healthcare-specialist companies.

The repeated presence of campaigns such as “Viagra Blue Brands”, “Relax Your Tight End” and “The Safe Pack” across different sections confirms the versatility of some of the year’s strongest pharmaceutical ideas. These entries compete not only through creativity, but through their ability to work across Integrated, Direct, Film, Brand Experience & Activation, Use of Humour and Patient Engagement.

Pharma Lions 2026 arrives at a decisive moment for the creative industry, as healthcare communication must balance impact, clarity, evidence, regulation, empathy and responsibility. In this context, the shortlist shows that the best pharmaceutical ideas are those that can be memorable without losing precision.

With this shortlist, Cannes Lions 2026 confirms that Pharma Lions is much more than a technical category. It is a space where creativity can translate science, shift perceptions, improve medical conversations and build bridges between pharmaceutical companies, healthcare professionals, patients and society.